ALT

Altimmune, Inc. (ALT)
Healthcare • Biotechnology • $2.87 • MCap: 558,140,800 🌐
https://altimmune.com • Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Buy Decision Core
Total Score
23
Business Quality
1
Financial Strength
10
Growth Outlook
1
Momentum
3
Price Action
Current
2.87
52W High
6.18
52W Low
2.59
Above 50DMA
2.91 (-1.41%)
Above 200DMA
3.82 (-24.80%)
Relative Strength
Relative Strength
-0.25
RS 3M
-0.18
RS 6M
-0.31
RS 9M
-0.28
RS 12M
-0.29
Fundamentals
Revenue Growth
0%
Earnings Growth
0%
ROE
-0.43%
ROA
-0.24%
Valuation
PE (Fwd)
-3.34
PEG
32.62
P/B
1.32
Upside
438.33%
Risk
Beta
0.24
Short %
0.25
Risk Score
6.00
Analyst
Rating
buy
Target
15.45
Beta
0.24
Analysts
0
Total Score
23
Upside
438.33%
Relative Strength
-0.25
Beta
0.24
Why Buy?
  • Analyst upside exceeds 15%
Key Risks
  • Negative ROE
  • Weak long-term relative strength
Score Breakdown
Business
1
Financial
10
Growth
1
Valuation
5
Risk
2
Momentum
3
Technical
52W High: 6.18
52W Low: 2.59
Above 50DMA: -1.41%
Above 200DMA: -24.80%
Valuation
Forward PE: -3.34
PEG: 32.62
P/B: 1.32
Upside: 438.33%
Risk
Beta: 0.24
Short Float: 0.25%
ROE: -0.43%
ROA: -0.24%